AZN
Price
$64.01
Change
-$1.01 (-1.55%)
Updated
Dec 5, 6:59 PM EST
65 days until earnings call
SNY
Price
$46.34
Change
-$0.68 (-1.45%)
Updated
Dec 5, 6:59 PM EST
58 days until earnings call
Ad is loading...

AZN vs SNY ᐉ Comparison: Which is Better to Invest?

Header iconAZN vs SNY Comparison
Open Charts AZN vs SNYBanner chart's image
AstraZeneca
Price$64.01
Change-$1.01 (-1.55%)
Volume$2.04M
CapitalizationN/A
Sanofi ADS
Price$46.34
Change-$0.68 (-1.45%)
Volume$705.32K
CapitalizationN/A
View a ticker or compare two or three
AZN vs SNY Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
AZN vs. SNY commentary
Dec 06, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a StrongBuy and SNY is a Hold.

COMPARISON
Comparison
Dec 06, 2023
Stock price -- (AZN: $64.01 vs. SNY: $46.34)
Brand notoriety: AZN: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 36% vs. SNY: 59%
Market capitalization -- AZN: $194.8B vs. SNY: $118.83B
AZN [@Pharmaceuticals: Major] is valued at $194.8B. SNY’s [@Pharmaceuticals: Major] market capitalization is $118.83B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $561.54B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $79.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • AZN’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, both AZN and SNY are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 3 bullish TA indicator(s).

  • AZN’s TA Score: 4 bullish, 2 bearish.
  • SNY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AZN is a better buy in the short-term than SNY.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а +1.12% price change this week, while SNY (@Pharmaceuticals: Major) price change was -1.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.17%. For the same industry, the average monthly price growth was +1.79%, and the average quarterly price growth was -8.34%.

Reported Earning Dates

AZN is expected to report earnings on Feb 08, 2024.

SNY is expected to report earnings on Feb 01, 2024.

Industries' Descriptions

@Pharmaceuticals: Major (+1.17% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for AZN with price predictions.
OPEN
A.I.dvisor published
a Summary for SNY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AZN($195B) has a higher market cap than SNY($119B). AZN has higher P/E ratio than SNY: AZN (33.44) vs SNY (11.88). SNY YTD gains are higher at: -0.717 vs. AZN (-3.591). SNY has higher annual earnings (EBITDA): 14.3B vs. AZN (13.6B). SNY has more cash in the bank: 7.99B vs. AZN (5.12B). SNY has less debt than AZN: SNY (21B) vs AZN (28.6B). SNY (45.7B) and AZN (45B) have equivalent revenues.
AZNSNYAZN / SNY
Capitalization195B119B164%
EBITDA13.6B14.3B95%
Gain YTD-3.591-0.717501%
P/E Ratio33.4411.88282%
Revenue45B45.7B98%
Total Cash5.12B7.99B64%
Total Debt28.6B21B136%
FUNDAMENTALS RATINGS
AZN vs SNY: Fundamental Ratings
AZN
SNY
OUTLOOK RATING
1..100
2065
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
1245
SMR RATING
1..100
5564
PRICE GROWTH RATING
1..100
5857
P/E GROWTH RATING
1..100
9481
SEASONALITY SCORE
1..100
n/a34

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (7) in the Pharmaceuticals Major industry is in the same range as AZN (17). This means that SNY’s stock grew similarly to AZN’s over the last 12 months.

AZN's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (45). This means that AZN’s stock grew somewhat faster than SNY’s over the last 12 months.

AZN's SMR Rating (55) in the Pharmaceuticals Major industry is in the same range as SNY (64). This means that AZN’s stock grew similarly to SNY’s over the last 12 months.

SNY's Price Growth Rating (57) in the Pharmaceuticals Major industry is in the same range as AZN (58). This means that SNY’s stock grew similarly to AZN’s over the last 12 months.

SNY's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as AZN (94). This means that SNY’s stock grew similarly to AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNSNY
RSI
ODDS (%)
Bullish Trend 6 days ago
70%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
47%
Momentum
ODDS (%)
Bullish Trend 1 day ago
58%
Bearish Trend 1 day ago
43%
MACD
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
46%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
44%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
39%
Advances
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 9 days ago
51%
Declines
ODDS (%)
Bearish Trend 8 days ago
48%
Bearish Trend 7 days ago
43%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
43%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLNE99.59-0.19
-0.19%
Hamilton Lane
BCE40.47-0.13
-0.32%
BCE
BWFG27.54-0.16
-0.58%
Bankwell Financial Group
REVG16.08-0.20
-1.23%
REV Group
ALPP0.90-0.03
-2.70%
Alpine 4 Holdings